These findings suggest that combinations of BTK inhibitors, BCL-2 antagonists, and/or anti-CD20 monoclonal antibodies should be tested clinically against CLL to increase antileukemic efficacy and reduce the risk of acquired resistance. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.